HC Wainwright Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Equities researchers at HC Wainwright began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a note issued to investors on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $38.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 216.67% from the stock’s previous close. HC Wainwright also issued estimates for Palvella Therapeutics’ Q4 2024 earnings at ($0.39) EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.11) EPS, FY2025 earnings at ($3.93) EPS, FY2026 earnings at ($4.12) EPS, FY2027 earnings at ($4.38) EPS and FY2028 earnings at ($2.62) EPS.

Separately, Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They set an “overweight” rating on the stock.

Palvella Therapeutics Trading Up 1.0 %

Shares of PVLA stock opened at $12.00 on Thursday. The stock has a market capitalization of $15.84 million, a price-to-earnings ratio of -0.99 and a beta of 0.61. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $22.32.

Insider Buying and Selling at Palvella Therapeutics

In other news, Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were bought at an average price of $12.93 per share, with a total value of $51,720.00. Following the acquisition, the director now owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.39% of the company’s stock.